Charles Schwab Investment Management Inc Denali Therapeutics Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,059,304 shares of DNLI stock, worth $29.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,059,304
Previous 1,041,059
1.75%
Holding current value
$29.9 Million
Previous $21.4 Million
15.14%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding DNLI
# of Institutions
214Shares Held
121MCall Options Held
127KPut Options Held
38.3K-
Baillie Gifford & CO13.8MShares$388 Million0.25% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$372 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$319 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.82MShares$277 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.13MShares$201 Million0.04% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.79B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...